Control of early gene expression of bacteriophage T4: involvement of the host rho factor and the mot gene of the bacteriophage.
Many early mRNA species of bacteriophage T4 are not synthesized after infection of Escherichia coli in the presence of chloramphenicol. This has been interpreted as a need for T4 protein(s) to be synthesized to allow expression of some early genes, e.g., those for deoxycytidinetriphosphatase, deoxynucleosidemonophosphate kinase and UDP-glucose-DNA beta-glucosyltransferase. In the experiments described here, early mRNA of bacteriophage T4 was allowed to accumulate during chloramphenicol treatment. After the addition of rifampin to inhibit further RNA synthesis, and subsequent removal of chloramphenicol, the accumulated mRNA was permitted to express itself into measured enzyme activities. It was shown that the early mRNA species coding for deoxycytidinetriphosphatase and UDP-glucose-DNA beta-glucosyltransferase could be formed in the presence of chloramphenicol if the E. coli host cell carried a mutation in the structural gene for the RNA chain termination factor rho. This was interpreted to mean that T4 protein(s) with anti-rho activity is normally required for the expression of these two early genes. An altered rho-factor could not, however, relieve the need of phage protein synthesis for the formation of another early mRNA, that coding for deoxynucleosidemonophosphate kinase. In this case the mot gene of T4 seemed to be involved, since the primary infection of E. coli cells with the mot gene mutant tsG1 did not allow subsequent deoxynucleoside monophosphate kinase mRNA synthesis after wild-type phage infection in the presence of chloramphenicol. In control experiments, deoxynucleoside monophosphate kinase mRNA synthesis induced by wild-type phage superinfecting in the presence of chloramphenicol was facilitated by the primary infection with T4 phage containing an unmutated mot gene.
D002701:Chloramphenicol / Q000494:pharmacology; D003845:Deoxycytosine Nucleotides / Q000235:genetics; D004926:Escherichia coli / Q000378:metabolism; D005786:Gene Expression Regulation; D005809:Genes, Regulator; D005964:Glucosyltransferases / Q000235:genetics; D009154:Mutation; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics; D010770:Phosphotransferases / Q000235:genetics; D017856:Phosphotransferases (Phosphate Group Acceptor); D011755:Pyrophosphatases; D012333:RNA, Messenger / Q000096:biosynthesis; D012234:Rho Factor / Q000235:genetics / Q000378:metabolism*; D012293:Rifampin / Q000494:pharmacology; D013604:T-Phages / Q000235:genetics*; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects; D014764:Viral Proteins / Q000096:biosynthesis
D003845:Deoxycytosine Nucleotides; D012333:RNA, Messenger; D012234:Rho Factor; D014157:Transcription Factors; D014764:Viral Proteins; D002701:Chloramphenicol; D005964:Glucosyltransferases; C026585:DNA beta-glucosyltransferase; D010770:Phosphotransferases; D017856:Phosphotransferases (Phosphate Group Acceptor); C020015:(deoxy)nucleoside-phosphate kinase; D010744:Phosphoric Monoester Hydrolases; D011755:Pyrophosphatases; C020007:dCTP pyrophosphatase; D012293:Rifampin